Literature DB >> 30951504

Evaluation of in-house loop-mediated isothermal amplification for tuberculosis diagnosis compared with Xpert MTB/RIF.

Charity Habeenzu1, Chie Nakajima2, Eddie Solo3, Precious Bwalya4, Kiichi Kajino5, Mari Miller6, Youichi Kurosawa7, Victor Mudenda8, Lackson Kasonka9, Yasuhiko Suzuki10, Takashi Matsuba11.   

Abstract

INTRODUCTION: To evaluate the diagnostic performances of an in-house loop-mediated isothermal amplification (LAMP) kit and the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in a resource-limited setting, this study was performed at the University Teaching Hospital, Ministry of Health, the Republic of Zambia.
METHODOLOGY: Two hundred sputum specimens obtained from new tuberculosis (TB) suspects were used for the evaluation of the diagnostic performance of an in-house LAMP kit in comparison with the Xpert MTB/RIF kit.
RESULTS: The sensitivity of in-house LAMP and Xpert MTB/RIF was 96.9% and 95.4% in smear-positive samples, 96.8% and 100% in smear-positive/culture-positive samples, and 39.1% and 73.9% in smear-negative/culture-positive samples, respectively. The specificity of in-house LAMP and MTB/RIF kits with culture was 96.5% and 94.5%, respectively. This indicated the superiority of the Xpert MTB/RIF kit; however, mechanical errors during sample processing and the insufficient quantity of samples by Xpert MTB/RIF kit occurred at 2.0% and 19.7%, respectively, comparing to the 100% accessibility of in-house LAMP.
CONCLUSIONS: Considering the results obtained in this study together with the easy setup with much simpler equipment, such as an aluminum heat block or water bath, in in-house LAMP compared with real-time polymerase chain reaction equipment in Xpert MTB/RIF kit, the applicability of in-house LAMP for the screening of tuberculosis directly from sputum in resource-limited setting seemed to be high. Copyright (c) 2017 Charity Habeenzu, Chie Nakajima, Eddie Solo, Precious Bwalya, Kiichi Kajino, Mari Miller, Youichi Kurosawa, Victor Mudenda, Lackson Kasonka, Yasuhiko Suzuki, Takashi Matsuba.

Entities:  

Keywords:  RIF; Xpert; Xpert MTB; in house LAMP; tuberculosis

Year:  2017        PMID: 30951504     DOI: 10.3855/jidc.7730

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  5 in total

1.  Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Mandy Yao; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

2.  Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2019-06-07

Review 3.  Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2018-08-27

4.  Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms.

Authors:  Adrienne E Shapiro; Jennifer M Ross; Mandy Yao; Ian Schiller; Mikashmi Kohli; Nandini Dendukuri; Karen R Steingart; David J Horne
Journal:  Cochrane Database Syst Rev       Date:  2021-03-23

5.  The performance of an in-house loop-mediated isothermal amplification for the rapid detection of Mycobacterium tuberculosis in sputum samples in comparison with Xpert MTB/RIF, microscopy and culture.

Authors:  Benjawan Phetsuksiri; Wiphat Klayut; Janisara Rudeeaneksin; Sopa Srisungngam; Supranee Bunchoo; Sarawut Toonkomdang; Thanee Wongchai; Chie Nakajima; Yasuhiko Suzuki
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2020-06-05       Impact factor: 1.846

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.